Oncorus is a biotechnology business based in the US. Oncorus shares (ONCR) are listed on the NASDAQ and all prices are listed in US Dollars. Oncorus employs 64 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.12 |
|---|---|
| 52-week range | $0.12 - $0.12 |
| 50-day moving average | $0.03 |
| 200-day moving average | $0.10 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.48 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.1206 from 2024-09-06
| 1 week (2024-09-01) | N/A |
|---|---|
| 1 month (2024-08-08) | N/A |
| 3 months (2024-06-08) | N/A |
| 6 months (2024-03-08) | N/A |
| 1 year (2023-09-12) | 360.31% |
|---|---|
| 2 years (2022-09-12) | -89.23% |
| 3 years (2021-09-10) | 10.17 |
| 5 years (2019-09-08) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -32.24% |
| Return on equity TTM | -124.56% |
| Profit margin | 0% |
| Book value | $1.19 |
| Market Capitalization | $3.3 million |
TTM: trailing 12 months
We're not expecting Oncorus to pay a dividend over the next 12 months.
Over the last 12 months, Oncorus's shares have ranged in value from as little as $0.1206 up to $0.1206. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncorus's is 1.954. This would suggest that Oncorus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Oncorus's beta into context you can compare it against those of similar companies.
Oncorus, Inc. , a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. .
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Check out the best-performing ETFs so far in 2024.
What to expect when you sign up for a Zacks Trade brokerage account.